450 related articles for article (PubMed ID: 8383657)
41. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.
Chen Z; Wu J; Zhang Y; Wei J; Leng X; Bi J; Li R; Yan L; Quan Z; Chen X; Yu Y; Wu Z; Liu D; Ma X; Maroko R; Cooper A
BMC Infect Dis; 2010 Jul; 10():217. PubMed ID: 20663130
[TBL] [Abstract][Full Text] [Related]
42. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
Siami FS; LaFleur BJ; Siami GA
Clin Ther; 2002 Jan; 24(1):59-72. PubMed ID: 11833836
[TBL] [Abstract][Full Text] [Related]
43. Safety and tolerability of ertapenem.
Teppler H; Gesser RM; Friedland IR; Woods GL; Meibohm A; Herman G; Mistry G; Isaacs R
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii75-81. PubMed ID: 15150186
[TBL] [Abstract][Full Text] [Related]
44. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
Philpott-Howard J; Burroughs A; Fisher N; Hastings M; Kibbler C; Mutimer D; Patch D; Rolando N; Wade J; Wendon J; O'Grady J
J Antimicrob Chemother; 2003 Dec; 52(6):993-1000. PubMed ID: 14585863
[TBL] [Abstract][Full Text] [Related]
45. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
Norrby SR; Finch RG; Glauser M
J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
[TBL] [Abstract][Full Text] [Related]
46. Piperacillin/tazobactam in the treatment of polymicrobial infections.
Gorbach SL
Intensive Care Med; 1994 Jul; 20 Suppl 3():S27-34. PubMed ID: 7962986
[TBL] [Abstract][Full Text] [Related]
47. A Non-inferiority Pilot Study Comparing the Clinical Efficacy and Safety of Generic Wide-spectrum Antibiotic Use in Septic Oncology Patients.
Araya I; Fasce G; Núñez E; Opazo JL; Saez E; Hurtado V; Contreras S; Quiñones LA
Drug Res (Stuttg); 2015 Dec; 65(12):635-9. PubMed ID: 25811220
[TBL] [Abstract][Full Text] [Related]
48. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Pillay T; Pillay DG; Adhikari M; Sturm AW
Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
[TBL] [Abstract][Full Text] [Related]
49. [Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].
Liu Y; Wang R; Yu B
Zhonghua Yi Xue Za Zhi; 2001 Jan; 81(1):41-4. PubMed ID: 11798851
[TBL] [Abstract][Full Text] [Related]
50. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
51. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group.
Sweet RL; Roy S; Faro S; O'Brien WF; Sanfilippo JS; Seidlin M
Obstet Gynecol; 1994 Feb; 83(2):280-6. PubMed ID: 8290195
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
Vestweber KH; Grundel E
Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
[TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
[TBL] [Abstract][Full Text] [Related]
54. Piperacillin/tazobactam in complicated urinary tract infections.
Nowé P
Intensive Care Med; 1994 Jul; 20 Suppl 3():S39-42. PubMed ID: 7962988
[TBL] [Abstract][Full Text] [Related]
55. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
Perry CM; Markham A
Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
[TBL] [Abstract][Full Text] [Related]
56. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
[TBL] [Abstract][Full Text] [Related]
57. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and tolerability of imipenem-cilastatin versus clindamycin+gentamicin for serious pelvic infections.
Larsen JW; Gabel-Hughes K; Kreter B
Clin Ther; 1992; 14(1):90-6. PubMed ID: 1576631
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia.
Wise R
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():97-104. PubMed ID: 8383659
[TBL] [Abstract][Full Text] [Related]
60. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA
Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
